Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/30/2025

Guideline for Surveillance of Gastric Intestinal Metaplasia (GIM)

Indications for Surveillance

Risk Stratification

Surveillance Protocol

Follow‑up Recommendations

Epidemiology & Outcomes

Shared Decision‑Making

Management of Gastric Intestinal Metaplasia

Risk Stratification and Management

  • The American Gastroenterological Association recommends testing and treating all patients with gastric intestinal metaplasia for H. pylori infection, as this is the only proven non-endoscopic intervention to reduce gastric cancer risk, with moderate quality evidence 6, 7.
  • Patients with high-risk features, such as corpus-extended GIM or OLGIM stages III/IV, incomplete GIM subtype, first-degree family history of gastric cancer, persistent/refractory H. pylori infection, or being from racial/ethnic minorities or immigrants from high gastric cancer incidence regions, should undergo endoscopic surveillance every 3 years 6, 7, 8, 9.
  • The majority of patients with limited, antral-only GIM without high-risk factors do not require routine surveillance endoscopy, based on a conditional recommendation with very low quality evidence 6, 7, 9.

H. Pylori Eradication and Surveillance

  • The European Society of Gastrointestinal Endoscopy recommends H. pylori eradication as a strong recommendation with moderate quality evidence, as it is the only intervention proven to reduce progression to dysplasia and gastric cancer 6, 7.
  • Surveillance endoscopy should be performed every 3 years in high-risk patients, with systematic biopsies, to identify prevalent neoplastic lesions and stage the extent of preneoplastic conditions 6, 8.

Lifestyle Modifications and Common Pitfalls

  • The American College of Gastroenterology suggests lifestyle modifications, such as dietary changes, smoking cessation, and limiting alcohol consumption, although evidence is limited 6, 7, 9.
  • Common pitfalls to avoid include performing routine surveillance on all patients with GIM, assuming GIM detected incidentally has been adequately staged, neglecting H. pylori testing, and using histologic staging systems inconsistently 6, 7, 9.